Editor's note: Seeking Alpha is proud to welcome Matthew Fry as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Premium. Click
Bausch Health Companies: 2022's Most Compelling Special Situation
Summary
- BHC’s stake in BLCO that is set to be distributed to shareholders is worth more than the current market capitalization of the entirety of BHC, giving investors a compelling return.
- The BLCO spinoff and Solta Medical IPO proceeds are sufficient for BHC to shoulder its approximately $20 billion debt load.
- BHC's intrinsic value is more than its current market capitalization, even if a distribution of BLCO and an IPO of Solta Medical do not materialize.
Undergraduate Student studying Finance. I write about special situations, deep and growth value stocks as well as short ideas.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of BHC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.